We acknowledge the limitation of our study, including the small cohort of patients receiving PD-1/PD-L1 therapy, its focus on late-stage lung cancer, and the lack of mechanistic insights into the roles of PD-L1+ CTECs to therapeutic resistance and PD-L1+ WBCs to inflammatory. Here, CD274 is linked to lung carcinoma.